Cingulate Inc

Research Cingulate Inc (CING) on Bullrun: market cap USD 70.63M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerCING
• ExchangeNASDAQ
• CountryUnited States
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 70.63M
• Financial periodFY2025
• Net income-USD 22.45M
• Free cash flow-USD 17.41M

Valuation Snapshot

latest market cap is USD 70.63M.

About Cingulate Inc

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety.

Frequently asked questions

What is Cingulate Inc's market cap?

Cingulate Inc's market capitalization is USD 70.63M.

What does Cingulate Inc do?

Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States.